Spangler S K, Jacobs M R, Appelbaum P C
Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033.
Antimicrob Agents Chemother. 1994 Oct;38(10):2471-6. doi: 10.1128/AAC.38.10.2471.
Agar dilution was used to compare the in vitro activity of CP 99,219 with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. CP 99,219 yielded a MIC for 50% of the strains tested (MIC50) of 0.25 micrograms/ml and a MIC90 of 1.0 microgram/ml, with 99.6% of the strains susceptible at a breakpoint of 2.0 micrograms/ml. Ciprofloxacin and grepafloxacin were less active (MIC50, 4.0 micrograms/ml; MIC90, 32.0 micrograms/ml and 2.0 and 16.0 micrograms/ml, respectively). Metronidazole was active against all gram-negative rods (MIC90, 4.0 micrograms/ml), but 31% of the gram-positive anaerobes were resistant at > 8.0 micrograms/ml. Cefoxitin was active against 84% of all strains at < or = 16.0 micrograms/ml, with a MIC50 of 4.0 micrograms/ml and a MIC90 of 32.0 micrograms/ml. Tazobactam enhanced the activity of piperacillin against > 95% of the beta-lactamase-producing gram-negative anaerobic rods (MIC90, 16.0 micrograms/ml).
采用琼脂稀释法比较了CP 99,219与环丙沙星、格帕沙星、甲硝唑、头孢西丁、哌拉西林以及哌拉西林-他唑巴坦对489株厌氧菌的体外活性。CP 99,219对50%受试菌株的最低抑菌浓度（MIC50）为0.25微克/毫升，MIC90为1.0微克/毫升，在2.0微克/毫升的折点浓度下，99.6%的菌株敏感。环丙沙星和格帕沙星活性较低（MIC50分别为4.0微克/毫升和2.0微克/毫升；MIC90分别为32.0微克/毫升和16.0微克/毫升）。甲硝唑对所有革兰氏阴性杆菌均有活性（MIC90为4.0微克/毫升），但31%的革兰氏阳性厌氧菌在>8.0微克/毫升时耐药。头孢西丁在≤16.0微克/毫升时对84%的菌株有活性，MIC50为4.0微克/毫升，MIC90为32.0微克/毫升。他唑巴坦增强了哌拉西林对>95%产β-内酰胺酶革兰氏阴性厌氧杆菌的活性（MIC90为16.0微克/毫升）。
